Could Capricor Therapeutics Incorporated (NASDAQ:CAPR) Skyrocket? The Stock Has Too Many Sellers

September 17, 2017 - By Henry Gaston

 Could Capricor Therapeutics Incorporated (NASDAQ:CAPR) Skyrocket? The Stock Has Too Many Sellers

Investors sentiment decreased to 1 in 2016 Q4. Its down 0.33, from 1.33 in 2016Q3. It dived, as 4 investors sold Capricor Therapeutics Inc shares while 2 reduced holdings. 2 funds opened positions while 4 raised stakes. 764,994 shares or 9.01% less from 840,701 shares in 2016Q3 were reported.
Perceptive Lc owns 4,000 shares. Vanguard accumulated 50,790 shares. Moreover, Blackrock Fund has 0% invested in Capricor Therapeutics Inc (NASDAQ:CAPR). Blackrock Advsrs Ltd Liability has 1,665 shares for 0% of their portfolio. Geode Cap Mngmt Ltd Co accumulated 43,929 shares. Fincl Architects invested in 0% or 2,000 shares. Susquehanna International Grp Inc Ltd Liability Partnership reported 14,319 shares. Brown Advisory reported 71,065 shares. Sabby Management Limited Liability Company reported 372,046 shares. Morgan Stanley holds 39,000 shares or 0% of its portfolio. Granite Point Cap Management L P holds 0.14% or 67,500 shares. Financial Bank Of America Corporation De reported 3,000 shares. Blackrock Invest Lc owns 410 shares or 0% of their US portfolio. Goldman Sachs Group invested in 75,561 shares or 0% of the stock. Cordasco Financial Net reported 3,100 shares stake.

Since May 9, 2017, it had 3 buys, and 0 selling transactions for $3.66 million activity. On Tuesday, May 9 Manzo Louis bought $31,000 worth of Capricor Therapeutics Inc (NASDAQ:CAPR) or 10,000 shares. The insider CEDARS SINAI MEDICAL CENTER bought $3.55M. Musket David B bought $77,500 worth of stock or 25,000 shares.

The stock of Capricor Therapeutics Incorporated (NASDAQ:CAPR) registered an increase of 16.72% in short interest. CAPR’s total short interest was 916,400 shares in September as published by FINRA. Its up 16.72% from 785,100 shares, reported previously. With 175,700 shares average volume, it will take short sellers 5 days to cover their CAPR’s short positions. The short interest to Capricor Therapeutics Incorporated’s float is 8.88%.

The stock increased 3.09% or $0.03 on September 15, reaching $1. About 1.08M shares traded or 265.46% up from the average. Capricor Therapeutics Inc (NASDAQ:CAPR) has declined 72.31% since September 17, 2016 and is downtrending. It has underperformed by 89.01% the S&P500.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm focused on the discovery, development and commercialization of therapeutics. The company has market cap of $23.50 million. The Firm focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. It currently has negative earnings. The Company’s product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction , while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure.

Capricor Therapeutics Inc (NASDAQ:CAPR) Ratings Coverage

Among 2 analysts covering Capricor Therapeutics (NASDAQ:CAPR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Capricor Therapeutics had 4 analyst reports since June 15, 2016 according to SRatingsIntel. Roth Capital initiated the shares of CAPR in report on Wednesday, June 15 with “Buy” rating. The firm has “Buy” rating given on Wednesday, July 6 by H.C. Wainwright. The stock of Capricor Therapeutics Inc (NASDAQ:CAPR) earned “Buy” rating by H.C. Wainwright on Monday, July 10. The rating was maintained by H.C. Wainwright on Friday, September 15 with “Buy”.

More notable recent Capricor Therapeutics Inc (NASDAQ:CAPR) news were published by: Prnewswire.com which released: “Capricor Therapeutics Completes Enrollment in Phase II ALLSTAR Clinical Trial” on October 05, 2016, also Thestreet.com with their article: “Capricor Therapeutics Stock Surging on Positive Muscular Dystrophy Trial Results” published on April 25, 2017, Seekingalpha.com published: “Capricor Therapeutics’ (CAPR) CEO Dr. Linda Marbán on Q2 2017 Results …” on August 11, 2017. More interesting news about Capricor Therapeutics Inc (NASDAQ:CAPR) were released by: Prnewswire.com and their article: “Capricor Therapeutics Announces Plans to Expand Clinical Development Program …” published on November 10, 2016 as well as Prnewswire.com‘s news article titled: “Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for …” with publication date: July 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.